Scancell Holdings PLC
LSE:SCLP

Watchlist Manager
Scancell Holdings PLC Logo
Scancell Holdings PLC
LSE:SCLP
Watchlist
Price: 9.9 GBX Market Closed
Market Cap: 102.7m GBX

Net Margin
Scancell Holdings PLC

-260.5%
Current
-99%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-260.5%
=
Net Income
-12.3m
/
Revenue
4.7m

Net Margin Across Competitors

No Stocks Found

Scancell Holdings PLC
Glance View

Market Cap
102.6m GBX
Industry
Biotechnology

Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire and currently employs 25 full-time employees. The company went IPO on 2010-07-30. The firm is focused on developing immunotherapies for the treatment of cancer and infectious disease. The Company’s technology includes ImmunoBody, Moditope, and AvidiMab, Its product pipeline includes SCIB1, SCIB2, Modi-1, Modi-2 and SCOV1& SCOV2 (COVIDITY). Its lead ImmunoBody cancer vaccine, SCIB1, is developed for the treatment of patients with metastatic melanoma. SCIB1 consists of SCIB1-001 and SCIB1-002. Its SCIB2 is the second cancer vaccine based on the ImmunoBody technology. SCIB2 vaccine is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer (NSCLC). Modi-1 is based on Moditope platform, which is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. Modi-2 targets homocitrullinated cancer antigens, to address different cancer indications to Modi-1, including tumors.

SCLP Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-260.5%
=
Net Income
-12.3m
/
Revenue
4.7m
What is the Net Margin of Scancell Holdings PLC?

Based on Scancell Holdings PLC's most recent financial statements, the company has Net Margin of -260.5%.

Back to Top